Anti-angiogenic drugs in cancer therapeutics: a review of the latest preclinical and clinical studies of anti-angiogenic agents with anticancer potential

Cancer is a group of diseases with significant morbidity and mortality. In cancer cells, where energy requirements are exceptionally high, angiogenesis, which the sprouting new blood vessels from pre-existing ones, an important process for tumour survival progression. Hence, extensive research in recent years focuses on discovery anticancer drugs that target angiogenesis. Several methodologies have been developed preclinically, including inhibition pro-angiogenic factors their receptors via micromolecular agents or monoclonal antibodies other compensatory pathways beyond traditional angiogenic ones. The purpose literature review to present angiogenesis under preclinical clinical investigation during last five years. Many targeting identified literature. results vitro vivo evaluation these show that, apart inhibiting they also affect cell proliferation growth. Recent studies increase overall disease-free patients, even those persistent, chemotherapy-resistant metastatic types cancer, although treatment-related side effects not uncommon. Drugs likely be future therapy, especially cases more treatments do produce desired combination regimens anti-angiogenic standard chemotherapeutics patient survival.